Supportive medications and interventions received by prostate cancer survivors: results from the PiCTure study
Supportive medications and interventions received by prostate cancer survivors: results from the PiCTure study
复制标题
前列腺癌幸存者接受的支持性药物和干预措施:PiCture 研究的结果
DOI:
10.12788/jcso.0384
复制
发表时间:
2017
期刊:
影响因子:
--
通讯作者:
L. Sharp
中科院分区:
文献类型:
--
作者:
F. Drummond;A. Gavin;L. Sharp
Prostate cancer treatments are associated with various physical after-e ects, including urinary, sexual, and bowel symptoms.1 ese after-e ects can have an impact on survivors’ healthrelated quality of life (HRQoL).2 Pharmaceutical and surgical interventions are available to manage or ameliorate many of these after-e ects (eg, sildena
l citrate taken during and after radiotherapy improves sexual function),3 and their receipt has a positive impact on HRQoL.4 However, studies of clinicians suggest that such interventions may not be used widely.5,6 Patientreported data on this topic is lacking. erefore, we investigated the use of supportive medications and interventions in this population-based study of prostate cancer survivors. Methods e PiCTure (Prostate Cancer Treatment, Your Experience) study methods have been described elsewhere.7 Briey, 6,559 prostate cancer survivors 2-15 years after diagnosis (diagnosed during January 1, 1995-March 31, 2010, and alive in November 2011), identi
ed from population-based cancer registries in the Republic of Ireland and Northern Ireland, were invited to complete a postal survey. Information was sought on after-e ects (incontinence, impotence, gynaecomastia, hot ashes/sweats, bowel problems, depression) that had been experienced at any time after treatment. For each after-e ect, men were asked if they had received any medication or interventions to alleviate symptoms, and, if so, what they had received; examples of common interven-